Cue Biopharma
97 hedge funds and large institutions have $241M invested in Cue Biopharma in 2020 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 40 increasing their positions, 22 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
2.37% less ownership
Funds ownership: 66.16% → 63.79% (-2.4%)
17% less capital invested
Capital invested by funds: $291M → $241M (-$49.8M)
87% less call options, than puts
Call options by funds: $359K | Put options by funds: $2.72M
Holders
97
Holding in Top 10
2
Calls
$359K
Puts
$2.72M
Top Buyers
| 1 | +$5.98M | |
| 2 | +$3.79M | |
| 3 | +$2.46M | |
| 4 |
Millennium Management
New York
|
+$2.28M |
| 5 |
Goldman Sachs
New York
|
+$2.2M |
Top Sellers
| 1 | -$17.7M | |
| 2 | -$5.06M | |
| 3 | -$2.37M | |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$1.12M |
| 5 |
BL
Bleichroeder LP
New York
|
-$938K |